The major strengths of our study were the large sample size with comprehensive assessments of multiple NAFLD risk factors, such as visceral adiposity, insulin resistance, and PNPLA3, and the inclusion of an HIV-uninfected comparator group. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.